View Future GrowthArdelyx 過去の業績過去 基準チェック /06Ardelyxは23.3%の年平均成長率で業績を伸ばしているが、Biotechs業界はgrowingで17.9%毎年増加している。売上は成長しており、年平均59.6%の割合である。主要情報23.32%収益成長率45.27%EPS成長率Biotechs 業界の成長-14.59%収益成長率59.63%株主資本利益率-39.07%ネット・マージン-13.58%前回の決算情報31 Mar 2026最近の業績更新Ardelyx, Inc. to Report Q1, 2026 Results on Apr 30, 2026Apr 17Ardelyx, Inc. to Report Q4, 2025 Results on Feb 19, 2026Feb 05Ardelyx, Inc. to Report Q3, 2025 Results on Oct 30, 2025Oct 13+ 1 more updateArdelyx, Inc. to Report Q2, 2025 Results on Aug 04, 2025Jul 21Ardelyx, Inc. to Report Q1, 2025 Results on May 01, 2025Apr 17Ardelyx, Inc. to Report Q4, 2024 Results on Feb 20, 2025Jan 31すべての更新を表示Recent updatesArdelyx, Inc., Annual General Meeting, Jun 16, 2026May 04Ardelyx, Inc. Announces Executive ChangesApr 20Ardelyx, Inc. to Report Q1, 2026 Results on Apr 30, 2026Apr 17Ardelyx, Inc. Appoints Rajani Dinavahi, MD, as Chief Medical Officer, Effective April 1, 2026Apr 01Ardelyx, Inc. Announces Rapid And Meaningful Symptom Relief With Tenapanor In IBS-CMar 10Ardelyx, Inc. Provides Revenue Guidance for Full Year 2026Feb 20Ardelyx, Inc. to Report Q4, 2025 Results on Feb 19, 2026Feb 05Ardelyx, Inc. Announces First Patient Dosed in ACCEL: Phase 3 Chronic Idiopathic Constipation Study of IBSRELAJan 28Zydus Lifesciences Reportedly Eyes Acquisition of Ardelyx for $2.5 BillionJan 23Ardelyx, Inc. Announces Executive ChangesDec 19Ardelyx, Inc. Presents Data, Including Results from the First Real-World Study of XphozahNov 08Ardelyx, Inc. has filed a Follow-on Equity Offering in the amount of $100 million.Nov 04Ardelyx, Inc. Presents Data Supporting First-in-Class Retainagogue, IBSRELA at the American College of Gastroenterology's 2025 Annual MeetingOct 28Ardelyx, Inc. Appoints Sue Hohenleitner as Principal Financial Officer, Effective November 4, 2025Oct 15Ardelyx, Inc. to Report Q3, 2025 Results on Oct 30, 2025Oct 13+ 1 more updateArdelyx, Inc. Announces Executive ChangesAug 05+ 2 more updatesArdelyx, Inc. to Report Q2, 2025 Results on Aug 04, 2025Jul 21Ardelyx, Inc. Announces Executive AppointmentsJun 04Ardelyx, Inc. Presents Data Supporting IBSRELA (tenapanor) At Digestive Disease Week 2025 ConferenceMay 06Ardelyx, Inc., Annual General Meeting, Jun 18, 2025May 01Ardelyx, Inc. Appoints Merdad Parsey to Its Board of Directors, Effective April 28, 2025Apr 30Ardelyx, Inc. to Report Q1, 2025 Results on May 01, 2025Apr 17Ardelyx, Inc. to Present Post-Hoc Analysis of the Optimize Study Supporting XPHOZAH®? (Tenapanor)Apr 11Ardelyx, Inc. Announces Approval of A New Drug Application for TenapanoFeb 26Ardelyx, Inc. to Report Q4, 2024 Results on Feb 20, 2025Jan 31Insufficient new directors Dec 30Independent Chairman of the Board recently bought €942k worth of stock Nov 16New minor risk - Shareholder dilution Nov 03Third quarter 2024 earnings released: US$0.003 loss per share (vs US$0.03 profit in 3Q 2023) Nov 01Ardelyx, Inc. to Report Q3, 2024 Results on Oct 31, 2024Oct 17Ardelyx, Inc. to Present Additional Data Supporting First-In-Class XPHOZAH (tenapanor) for Adults with Chronic Kidney Disease on Dialysis at the American Society of Nephrology's Kidney WeekOct 16Ardelyx, Inc. Announces Publication of A Review Article Exploring the Patient Burden and Therapeutic Landscape of IBS-C in the U.S. in Clinical and Experimental GastroenterologyOct 09Robbins LLP Informs Ardelyx, Inc. Stockholders of the Class ActionAug 19Ardelyx, Inc. Appoints Eric Foster as Chief Commercial OfficerAug 08Second quarter 2024 earnings released: US$0.07 loss per share (vs US$0.08 loss in 2Q 2023) Aug 02Forecast breakeven date moved forward to 2025 Aug 02Ardelyx, Inc. Announces Publication of Two Plain Language Summaries from XPHOZAH®? (tenapanor) Clinical Trials in Current Medical Research and OpinionJul 31Ardelyx, Inc. to Report Q2, 2024 Results on Aug 01, 2024Jul 18Forecast breakeven date pushed back to 2026 Jul 04Ardelyx, Inc.(NasdaqGM:ARDX) dropped from Russell Small Cap Comp Value IndexJul 03+ 1 more updateArdelyx, Inc. Chooses Not to File for TDAPA to Preserve Patient Access to XPHOZAHJul 02Chief Medical Officer recently sold €295k worth of stock Jun 10Ardelyx, Inc. Announces Rodriguez Would Resign as Chief Commercial OfficerMay 25President recently sold €226k worth of stock May 24Insider recently sold €726k worth of stock May 12Forecast breakeven date pushed back to 2026 May 03First quarter 2024 earnings released: US$0.11 loss per share (vs US$0.13 loss in 1Q 2023) May 03Ardelyx, Inc., Annual General Meeting, Jun 14, 2024May 01Ardelyx, Inc. to Report Q1, 2024 Results on May 02, 2024Apr 20Ardelyx, Inc. Announces the Appointment of Mike Kelliher as Executive Vice President, Corporate Development and StrategyMar 26Ardelyx, Inc. announced that it has received $50 million in fundingMar 06Full year 2023 earnings released: US$0.30 loss per share (vs US$0.42 loss in FY 2022) Feb 23Ardelyx, Inc. to Report Q4, 2023 Results on Feb 22, 2024Feb 02Ardelyx Announces Departure of Geoffrey Block as Board MemberNov 14Ardelyx, Inc. Announces XPHOZAH(R) (tenapanor) Now Available in the United StatesNov 08Ardelyx Shares Positive Data from Studies of Xphozah®? (Tenapanor) At Asn Kidney Week 2023Nov 04Ardelyx, Inc. Provides Earnings Guidance for the Full Year 2023Nov 01Third quarter 2023 earnings released: EPS: US$0.03 (vs US$0.14 loss in 3Q 2022) Oct 31Ardelyx, Inc. to Report Q3, 2023 Results on Oct 31, 2023Oct 30Insufficient new directors Oct 27Ardelyx, Inc. Shares Positive Data on Symptom Response During Treatment with IBSRELA®? (tenapanor) for IBS-C and Hosts IBS-C Product Theater at ACG 2023Oct 24Ardelyx, Inc. Announces FDA Approval of XPHOZAH (tenapanor), a First-In-Class Phosphate Absorption InhibitorOct 18Ardelyx, Inc. Announces Publication of Positive Results from T3MPO-3 Long-Term Open-Label Safety Trial of Tenapanor for IBS-C in the Journal of Neurogastroenterology and MotilitySep 29New major risk - Shareholder dilution Aug 04Second quarter 2023 earnings released: US$0.08 loss per share (vs US$0.18 loss in 2Q 2022) Aug 03Ardelyx, Inc. to Report Q2, 2023 Results on Aug 02, 2023Jul 28Forecast breakeven date pushed back to 2025 May 30Ardelyx, Inc. Announces FDA Acceptance and Six-Month Review for Resubmission of its New Drug Application of XPHOZAH(R)May 18First quarter 2023 earnings released: US$0.13 loss per share (vs US$0.21 loss in 1Q 2022) May 05Full year 2022 earnings released: US$0.42 loss per share (vs US$1.52 loss in FY 2021) Mar 03FDA Grants Appeal for Ardelyx's XPHOZAH® (tenapanor)Dec 30Forecast to breakeven in 2024 Dec 30Ardelyx Provides Update on FDA Appeal for XPHOZAH (tenapanor) for the Control of Serum Phosphorus in Adult Patients with Chronic Kidney Disease on DialysisDec 17Ardelyx Announces FDA Advisory Committee Votes that the Benefits of XPHOZAH® (tenapanor) Outweigh its Risks for the Control of Serum Phosphorus in Adult Patients with Chronic Kidney Disease on DialysisNov 17High number of new directors Nov 16Third quarter 2022 earnings released: US$0.14 loss per share (vs US$0.42 loss in 3Q 2021) Nov 05Ardelyx Presents New Data Analyses At Kidney Week 2022, Further Supporting the Clinical Relevance of Xphozah(R) (Tenapanor)Nov 04Ardelyx, Inc Announces Submission of New Drug Application for Tenapanor for Hyperphosphatemia in JapanNov 01Ardelyx, Inc. to Report Q3, 2022 Results on Nov 03, 2022Oct 28Ardelyx, Inc. to Present Poster Presentations on IBSRELA (Tenapanor) for Adult Patients with IBS-C At the American College of Gastroenterology 2022 Annual Scientific MeetingOct 25Second quarter 2022 earnings released: US$0.18 loss per share (vs US$0.45 loss in 2Q 2021) Aug 06President recently sold €63k worth of stock Jun 10Ardelyx Receives Letter from the Nasdaq Global MarketMay 29First quarter 2022 earnings released: US$0.21 loss per share (vs US$0.34 loss in 1Q 2021) May 07Ardelyx, Inc., Annual General Meeting, Jun 15, 2022May 02High number of new directors Apr 27Ardelyx Announces FDA Plan to Convene Advisory Committee for XPHOZAH(R) (tenapanor)Apr 26Ardelyx, Inc. Completes Three Successful Phase 3 Pivotal Trials, and Two Additional Phase 4 Clinical Trials (OPTIMIZE and NORMALIZE) for XPHOZAHApr 08Ardelyx Announces US Launch of IBSRELA®, a New First-in-Class Treatment for IBS-C in AdultsApr 05Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat Mar 02Ardelyx, Inc. to Report Q4, 2021 Results on Feb 28, 2022Feb 24Ardelyx, Inc. Receives an Appeal Denied Letter from the Office of Cardiology, Hematology, Endocrinology and Nephrology of the U.S. Food and Drug AdministrationFeb 11Ardelyx Announces Launching of IBSRELA® Second Quarter of 2022Dec 01Third quarter 2021 earnings released: US$0.42 loss per share (vs US$0.20 loss in 3Q 2020) Nov 13Ardelyx Announces Publication of 52-Week Phase 3 PHREEDOM TrialSep 04Second quarter 2021 earnings released: US$0.45 loss per share (vs US$0.28 loss in 2Q 2020) Aug 14収支内訳Ardelyx の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。収益と収入の歴史DB:41X 収益、費用、利益 ( )USD Millions日付収益収益G+A経費研究開発費31 Mar 26428-58356531 Dec 25407-62337030 Sep 25398-57327030 Jun 25386-56308031 Mar 25362-54289031 Dec 24334-39259030 Sep 24252-73230030 Jun 24210-65198031 Mar 24159-66161031 Dec 23124-66134030 Sep 23134-27106030 Jun 2383-5692031 Mar 2363-6684031 Dec 2252-6777030 Sep 229-11475030 Jun 225-13573031 Mar 224-15375031 Dec 2110-15869030 Sep 2111-15166030 Jun 2112-12556031 Mar 2113-10543031 Dec 208-9433030 Sep 208-8529030 Jun 208-9128031 Mar 206-9126031 Dec 195-9524030 Sep 193-103232230 Jun 190-104224031 Mar 190-100235631 Dec 183-9124030 Sep 1845-53246430 Jun 1844-50246231 Mar 1844-53236631 Dec 1742-64237530 Sep 170-1062315030 Jun 170-1142113431 Mar 170-1172111431 Dec 160-112199430 Sep 160-9818030 Jun 160-8717031 Mar 1618-5015031 Dec 1524-30143930 Sep 1530-1612030 Jun 15382110質の高い収益: 41Xは現在利益が出ていません。利益率の向上: 41Xは現在利益が出ていません。フリー・キャッシュフローと収益の比較過去の収益成長分析収益動向: 41Xは利益を出していないが、過去 5 年間で年間23.3%の割合で損失を削減してきた。成長の加速: 41Xの過去 1 年間の収益成長を 5 年間の平均と比較することはできません。現在は利益が出ていないためです。収益対業界: 41Xは利益が出ていないため、過去 1 年間の収益成長をBiotechs業界 ( 45% ) と比較することは困難です。株主資本利益率高いROE: 41Xは現在利益が出ていないため、自己資本利益率 ( -39.07% ) はマイナスです。総資産利益率使用総資本利益率過去の好業績企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 、過去の業績が好調な企業。View Financial Health企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/04 05:23終値2026/05/04 00:00収益2026/03/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Ardelyx, Inc. 10 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。18 アナリスト機関Julian HarrisonBTIGPrakhar AgrawalCantor Fitzgerald & Co.Yigal NochomovitzCitigroup Inc15 その他のアナリストを表示
Ardelyx, Inc. Announces First Patient Dosed in ACCEL: Phase 3 Chronic Idiopathic Constipation Study of IBSRELAJan 28
Ardelyx, Inc. Presents Data Supporting First-in-Class Retainagogue, IBSRELA at the American College of Gastroenterology's 2025 Annual MeetingOct 28
Ardelyx, Inc. Appoints Sue Hohenleitner as Principal Financial Officer, Effective November 4, 2025Oct 15
Ardelyx, Inc. Presents Data Supporting IBSRELA (tenapanor) At Digestive Disease Week 2025 ConferenceMay 06
Ardelyx, Inc. to Present Post-Hoc Analysis of the Optimize Study Supporting XPHOZAH®? (Tenapanor)Apr 11
Ardelyx, Inc. to Present Additional Data Supporting First-In-Class XPHOZAH (tenapanor) for Adults with Chronic Kidney Disease on Dialysis at the American Society of Nephrology's Kidney WeekOct 16
Ardelyx, Inc. Announces Publication of A Review Article Exploring the Patient Burden and Therapeutic Landscape of IBS-C in the U.S. in Clinical and Experimental GastroenterologyOct 09
Ardelyx, Inc. Announces Publication of Two Plain Language Summaries from XPHOZAH®? (tenapanor) Clinical Trials in Current Medical Research and OpinionJul 31
Ardelyx, Inc. Announces the Appointment of Mike Kelliher as Executive Vice President, Corporate Development and StrategyMar 26
Ardelyx, Inc. Shares Positive Data on Symptom Response During Treatment with IBSRELA®? (tenapanor) for IBS-C and Hosts IBS-C Product Theater at ACG 2023Oct 24
Ardelyx, Inc. Announces FDA Approval of XPHOZAH (tenapanor), a First-In-Class Phosphate Absorption InhibitorOct 18
Ardelyx, Inc. Announces Publication of Positive Results from T3MPO-3 Long-Term Open-Label Safety Trial of Tenapanor for IBS-C in the Journal of Neurogastroenterology and MotilitySep 29
Ardelyx, Inc. Announces FDA Acceptance and Six-Month Review for Resubmission of its New Drug Application of XPHOZAH(R)May 18
Ardelyx Provides Update on FDA Appeal for XPHOZAH (tenapanor) for the Control of Serum Phosphorus in Adult Patients with Chronic Kidney Disease on DialysisDec 17
Ardelyx Announces FDA Advisory Committee Votes that the Benefits of XPHOZAH® (tenapanor) Outweigh its Risks for the Control of Serum Phosphorus in Adult Patients with Chronic Kidney Disease on DialysisNov 17
Ardelyx Presents New Data Analyses At Kidney Week 2022, Further Supporting the Clinical Relevance of Xphozah(R) (Tenapanor)Nov 04
Ardelyx, Inc Announces Submission of New Drug Application for Tenapanor for Hyperphosphatemia in JapanNov 01
Ardelyx, Inc. to Present Poster Presentations on IBSRELA (Tenapanor) for Adult Patients with IBS-C At the American College of Gastroenterology 2022 Annual Scientific MeetingOct 25
Ardelyx, Inc. Completes Three Successful Phase 3 Pivotal Trials, and Two Additional Phase 4 Clinical Trials (OPTIMIZE and NORMALIZE) for XPHOZAHApr 08
Ardelyx, Inc. Receives an Appeal Denied Letter from the Office of Cardiology, Hematology, Endocrinology and Nephrology of the U.S. Food and Drug AdministrationFeb 11